Allecra has published the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections (cUTIs) in the Journal of the American Medical Association (JAMA).
Allecra Publishes Final Phase 3 ALLIUM Data in JAMA
Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer
Dr. de Min brings over 25 years’ experience in drug development in both big pharma and biotech. She will drive the advancement of Topas’ development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease.
Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties. Advanz gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway